GFB-887

DRUG3 trials

Sponsors

Goldfinch Bio, Inc.

Conditions

Diabetes ComplicationsDiabetes MellitusDiabetic NephropathiesEndocrine System DiseasesFocal Segmental NephrosisGlomerulonephritisGlomerulosclerosisGlomerulosclerosis, Focal Segmental

Phase 1

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

CompletedNCT03970122

Goldfinch Bio, Inc.Healthy Volunteers

Start: 2019-05-29End: 2020-04-04Updated: 2020-06-02

Phase 2

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

TerminatedNCT04387448

Goldfinch Bio, Inc.Diabetes Complications, Diabetes Mellitus, Diabetic Nephropathies +8

Start: 2020-07-28End: 2022-11-01Updated: 2022-11-15

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

TerminatedNCT04950114

Goldfinch Bio, Inc.Focal Segmental Nephrosis, Glomerulonephritis, Glomerulosclerosis +4

Start: 2021-07-27End: 2022-11-02Updated: 2022-11-15

Related Papers

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.

2021-07-2330 citations